| OA06.05 | A phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginally | Oral Abstract Session | Clinical trial results |
| OA07.01 | SMS reminders did not improve PrEP adherence in a randomized controlled trial among young Kenyan women | Oral Abstract Session | Behavioural and social science research |
| OA07.02 | “I just decided to stop:” Understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya and its implications for a public health approach to prevention | Oral Abstract Session | Behavioural and social science research |
| OA07.03 | Limited Knowledge of, Interest in, and Eligibility for Event-Driven PrEP among MSM in Two Samples in the United States | Oral Abstract Session | Behavioural and social science research |
| OA07.04 | I'm taking PrEP for myself and not for people: PrEP disclosures influence adherence journeys for adolescent girls and young women in South Africa | Oral Abstract Session | Behavioural and social science research |
| OA07.05LB | High initiation and persistence on pre-exposure prophylaxis (PrEP) in HIV-uninfected pregnant women in Cape Town, South Africa | Oral Abstract Session | Implementation science, including structural interventions, PrEP & VMMC |
| OA08.01 | Antibody isotype switching as a mechanism to counter HIV neutralization escape | Oral Abstract Session | Humoral immunity |
| OA08.02 | Vaccination induces maturation of diverse unmutated VRC01-class precursors to HIV-1 broadly neutralizing antibodies in an Ig-humanized mouse model | Oral Abstract Session | Broadly neutralizing antibodies |
| OA08.03 | Combinations of scFv of HIV bNAbs demonstrate high breadth and potency against a multiclade panel of viruses | Oral Abstract Session | Broadly neutralizing antibodies |
| OA08.04 | Active tuberculosis co-infection enhances HIV-1 specific humoral immunity | Oral Abstract Session | Humoral immunity |